Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.
Sanofi-Aventis Investigational Site Number 233003, Tartu, Estonia
Sanofi-Aventis Investigational Site Number 152007, Valparaiso, Chile
Sanofi-Aventis Investigational Site Number 246005, Järvenpää, Finland
Research Site, Seattle, Washington, United States
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Medical Dep M, Diabetes and Endocrinology Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark
Physical medicine & rehabilitation Dept AOU Maggiore della Carità, Novara, Italy
University of South Carolina School of Medicine, Columbia, South Carolina, United States
University of British Columbia, Vancouver, British Columbia, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.